Statin Use and the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study)

Acharya, Tushar; Huang, Jian; Tringali, Steven; Frei, Christopher R.; Mortensen, Eric M.; Mansi, Ishak A.

doi:10.1016/j.amjcard.2015.11.031

Cited by 39 publications

(40 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, increase in creatinine level was statistically significant by double-dose statin therapy without overt episodes of renal failure. Although the effects of statins on renal diseases including diabetic nephropathy are controversial, favorable effects [25] or non-favorable effects [26] are suggested by the use of longer terms. Thus the interpretation for creatinine changes in our analysis would require longer observation.…”

Section: Discussionmentioning

confidence: 99%

Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects

et al. 2017

View full text Add to dashboard Cite

Background: Lowering cholesterol levels decreases the risk of atherosclerotic diseases. Effective ways to stably reduce LDL-C level are warranted in type 2 diabetic patients, a high-risk population for CVD, with various anti-diabetic therapeutic background. The RESEARCH study focuses on LDL-C reduction in this population along with modifications of the lipid profiles. We evaluated long-term ezetimibe add-on therapy in T2DM patients with hypercholesterolemia. Methods: In a randomized, multicenter, open-label, prospective study, a total of 109 T2DM patients not attaining LDL-C target value despite first-line dose statin (10 mg of atorvastatin or 1 mg of pitavastatin) therapy in Japan were recruited. We investigated the difference in cholesterol lowering effect between ezetimibe (10 mg) add-on statin (EAT) group and double-dose statin (DST) group. Changes of parameters related to atherosclerotic event risks were assessed. Results: The reduction of LDL-C was larger in the EAT group (28.3%) than in the DST group (9.2%) at 52 weeks as well as the primary endpoint of 12 weeks. EAT achieved significant lower levels of TC and apo B, respectively. Both treatments attained significant reduction in sd-LDL-C or hsCRP on this long-term basis. Notably, sd-LDL-C in EAT reduced as low as 36.1 ± 14.9 mg/dl to reach near the threshold (35.0 mg/dl) for atherosclerosis with significantly higher achievement rate (55.6%) than DST treatment. Simultaneously, hsCRP reduction by EAT attained as low value as 0.52 ± 0.43 mg/l. Conclusions: In the present 52-week long-term period, ezetimibe add-on therapy showed a robust advantage in lowering LDL-C and in attaining target LDL-C values compared with the doubling of statin dose. Moreover, it's meaningful that sd-LDL, powerfully atherogenic lipoprotein, exhibited prominent decrease consistently prominently by ezetimibe add-on therapy. DM patients with hypercholesterolemia are at high risk for CAD, and adding ezetimibe onto usual-dose statin treatment in Japan has been suggested as the first-line therapy for those DM patients who failed to attain the target LDL-C value (UMIN000002593).

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The study methods have been previously published . Briefly, this was a retrospective cohort study using patients enrolled in the San Antonio Military Healthcare System from October 1, 2003, to March 1, 2012, after approval from institutional review boards of relevant institutions.…”

Section: Methodsmentioning

confidence: 99%

Statins and Lower Gastrointestinal Conditions: A Retrospective Cohort Study

Pearlman

Covin

Schmidt

et al. 2017

The Journal of Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Several studies have reported constipation, abdominal pain, or diarrhea as common adverse events for statins. Statins are among the most commonly prescribed medications, and the impact on the prevalence of these conditions was rarely studied as main outcomes. The aim of this study is to determine if statin therapy is associated with constipation, abdominal pain, diarrhea, or colitis. This was a retrospective cohort study using a regional military health care data from October 1, 2003, to March 1, 2012. A propensity score-matched cohort of statin users and nonusers was created based on 82 variables. The primary analysis evaluated the odds ratios of the following diagnoses: constipation, ≥3 encounters for constipation; abdominal pain, ≥3 encounters for abdominal pain; diarrhea, ≥3 encounters for diarrhea; colitis, ≥3 encounters for colitis; and endoscopy of the lower gastrointestinal tract, ≥3 endoscopies of the lower gastrointestinal tract. After propensity score matching of 6342 statin users and 6342 nonusers, there was no statistically significant difference in constipation (OR, 0.96; 95%CI, 0.87-1.05; P = .33), abdominal pain (OR, 0.95; 95%CI, 0.88-1.02; P = .15), or colitis (OR, 1.02; 95%CI, 0.91-1.14; P = .73). However, there was an association between statin therapy and endoscopy of the lower gastrointestinal tract (OR, 1.14; 95%CI, 1.04-1.26; P = .002) and decreased odds of diarrhea (OR, 0.88; 95%CI, 0.80-0.97; P = .01). In this retrospective cohort study, an association between statin therapy and increased likelihood of being diagnosed with lower gastrointestinal conditions could not be demonstrated, contrary to some statins package inserts.

show abstract

“…In a retrospective cohort study, Statins users had greater odds of acute kidney injury up to 30% and chronic kidney disease up to 36% and the authors suggested statins in long-term usage may show increase morbidity and mortality and increase incidence of CKD and diabetes mellitus due to statins usage [5]. Renal failure may occur in first 120 days of usage high potency statins: (≥ 10 mg rosuvastatin, ≥ 20 mg atorvastatin, and ≥ 40 mg simvastatin), this risk may be highest in the first year and remained high during first year of stopping treatment and then returned to normal 1-3 years after stopping treatment [2,4].…”

Section: Letter To Editormentioning

confidence: 99%

Statins Dangers and Kidney: A Need for Prescription Revision

Malaki¹

2017

Transl Med

View full text Add to dashboard Cite

with GFR under 60 and non-dialysis stage reviewed in a Cochrane Database Systemtic review in 2014 and showed Statin-related effects on stroke and kidney function were found to be uncertain and adverse effects of treatment are incompletely understood [6]. Statins cannot consider as a safe drug that prevent the harmful effects of dyslipidemia on kidney in short term or long term and should be remind JUPITAR trial [2] that show two years use of high dose statins in 450 case can prevent one death from vascular accidents, and we should justify benefits of high potency statins would outweigh the combined risk of acute kidney injury, rhabdomyolysis, and diabetes that enforce us to surveillance these side effects when we use statins.

show abstract

Statin Use and the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study)

Cited by 39 publications

References 24 publications

Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects

Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects

Statins and Lower Gastrointestinal Conditions: A Retrospective Cohort Study

Statins Dangers and Kidney: A Need for Prescription Revision

Contact Info

Product

Resources

About